Marion McCourt has been appointed senior vice president and head of commercial, Regeneron Pharmaceuticals. Ms. McCourt will lead all aspects of product commercialization for the company’s currently approved medicines and development-stage pipeline.

Ms. McCourt has more than two decades of experience in biopharmaceutical management with an emphasis on commercial strategy and execution. Most recently, she served as chief operating officer of Medivation until its acquisition by Pfizer in 2016, and as president and chief operating officer of Axovant, a clinical-stage biopharmaceutical company. She began her career with AstraZeneca, where she held positions of increasing responsibility over 12 years, becoming chief operating officer for AstraZeneca U.S. She also held commercial leadership roles at Amgen.   

“Marion is an accomplished biopharmaceutical executive who brings a track record of success in commercializing products and leading commercial teams,” said Leonard S. Schleifer, MD, Ph.D., president and chief executive officer of Regeneron. “With several marketed therapies for serious diseases and more than 15 late-stage programs that could result in new approvals or indications, Marion will play a critical role in shaping Regeneron’s future and ensuring our innovative medicines reach patients in need.”